Log In
BCIQ
Print this Print this
 

ASP1807, CC8464

  Manage Alerts
Collapse Summary General Information
Company Chromocell Corp.
DescriptionOral, peripherally-restricted inhibitor of NaV1.7
Molecular Target Nav1.7 (SCN9A)
Mechanism of ActionNav1.7 (SCN9A) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationPain
Indication DetailsManage neuropathic pain associated with idiopathic small fiber neuropathy; Treat neuropathic pain
Regulatory Designation U.S. - Fast Track (Manage neuropathic pain associated with idiopathic small fiber neuropathy)
PartnerAstellas Pharma Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$515.0M

$15.0M

$500.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/30/2015

$515.0M

$15.0M

$500.0M

Get a free BioCentury trial today